젠맙·애브비, 엡코리타맙과 R-CHOP 병용요법, 새로 진단된 미만성 거대 B세포 림프종 환자서 무진행 생존기간 통계적으로 유의미하게 개선…3상 시험서 질병 진행 또는 사망 위험 51% 감소

GENMAB AND ABBVIE SAY EPCORITAMAB IN COMBINATION WITH R-CHOP DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), WITH THE PHASE 3 TRIAL SHOWING A 51% REDUCTION IN THE RISK OF PROGRESSION OR DEATH